CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $10,951,125
- in 9 filings, $8.0M under 10b5-1 plans
Net −$10,951,125. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Cohen Joshua B −$4.0M Co-Chief Executive Officer sold 4% of stake
- Klee Justin B. −$4.0M Co-Chief Executive Officer sold 4% of stake
- FRATES JAMES M −$1.6M Chief Financial Officer sold 18% of stake
- MILNE GEORGE M JR −$831K Director sold 4% of stake
- Bedrosian Camille L −$325K Chief Medical Officer sold 3% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-10 | FRATES JAMES M Chief Financial Officer | Option exercise 10b5-1 | +20,000 | $6.88 | $138K | 253,625 |
| 2026-11-10 | FRATES JAMES M Chief Financial Officer | Sale 10b5-1 | −12,800 | $30.32 | $388K | 240,825 |
| 2026-11-10 | FRATES JAMES M Chief Financial Officer | Sale 10b5-1 | −7,200 | $30.97 | $223K | 233,625 |
| 2026-11-10 | FRATES JAMES M Chief Financial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −20,000 | 323,835 | ||
| 2026-11-09 | FRATES JAMES M Chief Financial Officer | Option exercise 10b5-1 | +20,000 | $6.88 | $138K | 253,625 |
| 2026-11-09 | FRATES JAMES M Chief Financial Officer | Sale 10b5-1 | −7,700 | $29.39 | $226K | 245,925 |
| 2026-11-09 | FRATES JAMES M Chief Financial Officer | Sale 10b5-1 | −12,300 | $30.11 | $370K | 233,625 |
| 2026-11-09 | FRATES JAMES M Chief Financial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −20,000 | 343,835 | ||
| 2026-11-09 | Klee Justin B. Co-Chief Executive Officer | Sale 10b5-1 | −37,483 | $29.39 | $1.1M | 3,575,573 |
| 2026-11-09 | Klee Justin B. Co-Chief Executive Officer | Sale 10b5-1 | −62,517 | $30.11 | $1.9M | 3,513,056 |
| 2026-11-09 | Cohen Joshua B Co-Chief Executive Officer | Sale 10b5-1 | −38,105 | $29.39 | $1.1M | 3,575,018 |
| 2026-11-09 | Cohen Joshua B Co-Chief Executive Officer | Sale 10b5-1 | −61,895 | $30.11 | $1.9M | 3,513,123 |
| 2026-10-05 | MILNE GEORGE M JR Director | Sale 10b5-1 | −30,000 | $27.70 | $831K | 782,881 |
| 2026-09-10 | Bedrosian Camille L Chief Medical Officer | Sale | −7,947 | $32.21 | $256K | 280,145 |
| 2026-09-10 | Bedrosian Camille L Chief Medical Officer | Sale | −2,081 | $33.09 | $69K | 278,064 |
| 2026-09-10 | FRATES JAMES M Chief Financial Officer | Sale | −9,768 | $32.27 | $315K | 234,667 |
| 2026-09-10 | FRATES JAMES M Chief Financial Officer | Sale | −1,042 | $33.23 | $35K | 233,625 |
| 2026-09-10 | Mazzariello Gina Chief Legal Officer | Sale | −9,525 | $32.46 | $309K | 190,849 |
| 2026-09-10 | Mazzariello Gina Chief Legal Officer | Sale | −11 | $33.34 | $367 | 190,838 |
| 2026-09-10 | Cohen Joshua B Co-Chief Executive Officer | Sale | −29,545 | $32.16 | $950K | 3,614,042 |
Page 1 of 19 · 362 trades